STAT3 Dysregulation in Mature T and NK Cell Lymphomas
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
T cell lymphomas comprise a distinct class of non-Hodgkin’s lymphomas, which include mature T and natural killer (NK) cell neoplasms. While each malignancy within this group is characterized by unique clinicopathologic features, dysregulation in the Janus tyrosine family of kinases/Signal transducer and activator of transcription (JAK/STAT) signaling pathway, specifically aberrant STAT3 activation, is a common feature among these lymphomas. The mechanisms driving dysregulation vary among T cell lymphoma subtypes and include activating mutations in upstream kinases or STAT3 itself, formation of oncogenic kinases which drive STAT3 activation, loss of negative regulators of STAT3, and the induction of a pro-tumorigenic inflammatory microenvironment. Constitutive STAT3 activation has been associated with the expression of targets able to increase pro-survival signals and provide malignant fitness. Patients with dysregulated STAT3 signaling tend to have inferior clinical outcomes, which underscores the importance of STAT3 signaling in malignant progression. Targeting of STAT3 has shown promising results in pre-clinical studies in T cell lymphoma lines, ex-vivo primary malignant patient cells, and in mouse models of disease. However, targeting this pleotropic pathway in patients has proven difficult. Here we review the recent contributions to our understanding of the role of STAT3 in T cell lymphomagenesis, mechanisms driving STAT3 activation in T cell lymphomas, and current efforts at targeting STAT3 signaling in T cell malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors RORα and RORγ
Yang, X. O., Pappu, B. P., Nurieva, R., Akimzhanov, A., Kang, H. S., Chung, Y., Ma, L., Shah, B., Panopoulos, A. D., Schluns, K. S., et al. (2008) · Immunity · doi:10.1016/j.immuni.2007.11.016 · Cited by 1,605
Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633 · cited 1×
“Treatment with an antisense oligo against STAT3 resulted in decreased STAT3 protein levels, decreased Mcl-1 protein levels, and increased sensitivity to Fas-mediated apoptosis in T-LGL cells [66].”
BackgroundJAK/STAT signaling in hematological malignancies
Vainchenker, W., & Constantinescu, S. N. (2013) · Oncogene · doi:10.1038/onc.2012.347 · Cited by 528
STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3
Liu, L., McBride, K. M., & Reich, N. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501643102 · Cited by 348 · cited 1×
“The STAT dimers are actively transported through the nuclear pores using importin α/β and RanGDP complexes [6].”
BackgroundNielsen, M., Kaltoft, K., Nordahl, M., Röpke, C., Geisler, C., Mustelin, T., Dobson, P., Svejgaard, A., & Ødum, N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6764 · Cited by 220
Self-citationAggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
Porpaczy, E., Tripolt, S., Hoelbl-Kovacic, A., Gisslinger, B., Bago-Horvath, Z., Casanova-Hevia, E., Clappier, E., Decker, T., Fajmann, S., Fux, D. A., et al. (2018) · Blood · doi:10.1182/blood-2017-10-810739 · Cited by 151
Real time analysis of STAT3 nucleocytoplasmic shuttling
Pranada, A. L., Metz, S., Herrmann, A., Heinrich, P. C., & Müller-Newen, G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312530200 · Cited by 140
STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma
Brender, C., Nielsen, M., Kaltoft, K., Mikkelsen, G., Zhang, Q., Wasik, M., Billestrup, N., & Ødum, N. (2001) · Blood · doi:10.1182/blood.v97.4.1056 · Cited by 129
Self-citationFeng, M.-G., Liu, C.-F., Chen, L., Feng, W.-B., Liu, M., Hai, H., & Lu, J.-M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.043 · Cited by 80
Cited by
The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
Jiang, N., Dai, Q., Su, X., Fu, J., Feng, X., & Peng, J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05435-1 · Cited by 571
Signal transducer and activator of transcription 3 signaling in tumor immune evasion
Zhang, L., Kuca, K., You, L., Zhao, Y., Musilek, K., Nepovimova, E., Wu, Q., Wu, W., & Adam, V. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107969 · Cited by 67
Kołkowski, K., Trzeciak, M., & Sokołowska-Wojdyło, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413388 · Cited by 30
Metadata
- Authors
- Seffens, A., Herrera, A., Tegla, C., Buus, T. B., Hymes, K. B., Ødum, N., Geskin, L. J., & Koralov, S. B.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-11-02
- Volume
- 11
- Issue
- 11
- Pages
- 1711
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2988773944
- Cited by
- 42
- References
- 9
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: STAT3 Dysregulation in Mature T and NK Cell Lymphomas. https://app.cochat.ai/papers/10.3390/cancers11111711
- The paper
- Seffens, A., Herrera, A., Tegla, C., Buus, T. B., Hymes, K. B., Ødum, N., Geskin, L. J., & Koralov, S. B. (2019). STAT3 Dysregulation in Mature T and NK Cell Lymphomas. Cancers. https://doi.org/10.3390/cancers11111711
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.